Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

Molecular Psychiatry
S MiyamotoJ A Lieberman

Abstract

Since the introduction of chlorpromazine and throughout the development of the new-generation antipsychotic drugs (APDs) beginning with clozapine, the D(2) receptor has been the target for the development of APDs. Pharmacologic actions to reduce neurotransmission through the D(2) receptor have been the only proven therapeutic mechanism for psychoses. A number of novel non-D(2) mechanisms of action of APDs have been explored over the past 40 years but none has definitively been proven effective. At the same time, the effectiveness of treatments and range of outcomes for patients are far from satisfactory. The relative success of antipsychotics in treating positive symptoms is limited by the fact that a substantial number of patients are refractory to current medications and by their lack of efficacy for negative and cognitive symptoms, which often determine the level of functional impairment. In addition, while the newer antipsychotics produce fewer motor side effects, safety and tolerability concerns about weight gain and endocrinopathies have emerged. Consequently, there is an urgent need for more effective and better-tolerated antipsychotic agents, and to identify new molecular targets and develop mechanistically novel compou...Continue Reading

References

Oct 1, 1991·The American Journal of Psychiatry·D C Javitt, S R Zukin
Nov 1, 1991·The American Journal of Psychiatry·K L DavisM Davidson
Jan 1, 1995·Acta Psychiatrica Scandinavica. Supplementum·W W Fleischhacker
Aug 17, 1995·Nature·G V Williams, P S Goldman-Rakic
Oct 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·S J DuinkerkeH L Busard
Nov 25, 1994·Journal of Medicinal Chemistry·P D Leeson, L L Iversen
Feb 1, 1993·Biological Psychiatry·J D HallonquistN A Rector
Mar 1, 1996·The American Journal of Psychiatry·M F Green
May 1, 1996·The British Journal of Psychiatry : the Journal of Mental Science·R E LitmanD Pickar
Jan 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·O BenkertH Wetzel
May 1, 1996·International Clinical Psychopharmacology·R W Buchanan, J M Gold
Nov 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·P W BurnetP J Harrison
Jul 1, 1997·Progress in Neurobiology·A Hashimoto, T Oka
Jan 1, 1996·Harvard Review of Psychiatry·J T Coyle
Nov 24, 1998·Journal of Neural Transmission·A C LahtiC A Tamminga
Dec 4, 1998·Biological Psychiatry·J A LiebermanJ E Kraus
Jan 30, 1999·Psychoneuroendocrinology·C S Carter
Jan 30, 1999·Psychoneuroendocrinology·K Uvnäs-Moberg
Feb 10, 1999·Psychopharmacology·D Feifel, T Reza
Mar 13, 1999·The Journal of Clinical Psychiatry·M S BauerB J Powell
Aug 11, 1999·Trends in Neurosciences·R Rupprecht, F Holsboer
Aug 26, 1999·Journal of Neurochemistry·R JanákyC A Shaw
Aug 26, 1999·Neuropharmacology·N M Barnes, T Sharp
Dec 11, 1999·Schizophrenia Research·P J Harrison

❮ Previous
Next ❯

Citations

Feb 6, 2013·European Archives of Psychiatry and Clinical Neuroscience·Alkomiet HasanSchahram Akbarian
May 23, 2013·Cell and Tissue Research·Christian T WentzWolfgang Kelsch
Jun 12, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ulrike StadlbauerUrs Meyer
Sep 27, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David M DietzEric J Nestler
Jan 5, 2013·Current Opinion in Psychiatry·Seiya MiyamotoW Wolfgang Fleischhacker
Jan 24, 2013·Therapeutic Advances in Chronic Disease·Erik Johnsen, Rune A Kroken
Jun 15, 2013·Neuropsychiatric Disease and Treatment·Tomomi TenjinNoboru Yamaguchi
Mar 20, 2013·Cellular and Molecular Life Sciences : CMLS·Lisa GherardiniTommaso Pizzorusso
Nov 28, 2013·Pharmacogenomics·Amy C C Kao, Daniel J Müller
Apr 30, 2014·Schizophrenia Bulletin·W Wolfgang FleischhackerPeter Woodruff
Jul 8, 2014·European Journal of Pharmacology·Hong Joon LeeSang June Hahn
Sep 17, 2014·ILAR Journal·Melinda A Novak, Jerrold S Meyer
Jul 30, 2014·Journal of Psychiatric Research·Seiya MiyamotoW Wolfgang Fleischhacker
Sep 13, 2013·Future Medicinal Chemistry·Abraham LópezErnest Giralt
Dec 24, 2013·Future Medicinal Chemistry·Pawel ZajdelAnna Wesolowska
Sep 13, 2014·European Archives of Psychiatry and Clinical Neuroscience·Mathias ZinkAndrea Schmitt
Sep 1, 2015·Schizophrenia Bulletin·Alexis C EdwardsAyman H Fanous
Dec 21, 2013·Expert Opinion on Pharmacotherapy·Naren P Rao, Gary Remington
Apr 29, 2015·Expert Review of Clinical Pharmacology·Mathias Zink, Christoph U Correll
Apr 14, 2015·Expert Opinion on Pharmacotherapy·Jan Malte BumbF Markus Leweke
Jul 15, 2015·Expert Opinion on Emerging Drugs·Jonathan Tomas Lockwood, Gary Remington
Sep 23, 2014·Expert Opinion on Emerging Drugs·Luisa-Sophie KösterChristoph U Correll
Apr 23, 2013·Expert Opinion on Drug Metabolism & Toxicology·Victor VoicuFlavian Ştefan Rădulescu
Feb 20, 2016·CNS Drugs·Paul D Shilling, David Feifel
Jan 19, 2016·Frontiers in Pharmacology·Clément E LemercierZoltan Gerevich
Sep 1, 2015·Journal of Medicinal Chemistry·Shibing TangSheng Ding
Jan 27, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Kristoffer SahlholmPeter Århem
Jul 2, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Su M ParkWilliam C Wetsel
Dec 15, 2015·Molecular and Cellular Neurosciences·Christa W HabelaGuo-Li Ming
Jan 3, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·David J G WatsonKevin C F Fone
Aug 5, 2015·Schizophrenia Bulletin·Marjaana A PeltolaHeikki Rauvala
Sep 1, 2015·Asian Journal of Psychiatry·Tricia L da Silva, Arun V Ravindran

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here